Clinical features and prognosis of multiple myeloma and orbital extramedullary disease: Seven cases report and review of literature

doi:10.12998/wjcc.v10.i33.12365

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 33

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3843)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

133

WORD

HTML

1440

Figures (1-2)

366

Tables (1-3)

307

Sum=2281

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

397

Download

1165

Sum=1562

Nov 26, 2022 (publication date) through Dec 18, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. Nov 26, 2022; 10(33): 12365-12374
Published online Nov 26, 2022. doi: 10.12998/wjcc.v10.i33.12365

Table 3 Treatment options and response

Case	Regimens	Treatment options	Response
1	VRD, ECHOP and lenalidomide maintenance therapy	Chemotherapy after surgery	PR
2	BAD and lenalidomide maintenance therapy	Chemotherapy and radiotherapy after surgery	PD soon after CR, then reached PR after undergoing Car-T therapy in another hospital
3	T-CAD, BAD and thalidomide maintenance therapy	Chemotherapy	CR
4	T-CAD and thalidomide maintenance therapy	Chemotherapy after surgery	CR
5	T-CAD, BAD, B-CEVAD and thalidomide maintenance therapy	Chemotherapy and radiotherapy after surgery	CR
6	T-CAD ,BAD and thalidomide maintenance therapy	Chemotherapy	CR
7	CAD,R-DECP, BED and lenalidomide maintenance therapy	Chemotherapy after surgery	CR

VRD: Bortezomib, Lenalidomide and Dexamethsone; BAD regimen (Bortezomib, Doxorubicin and Dexamethsone); CAD: Ifosfamide, Epirubicin or Piraubicin and Dexamethsone; T-CAD: Thalidomide and CAD; B-CEVAD: Bortezomib, Etoposide, ifosfamide, Vindesine sulfate, Epirubicin, and Dexamethsone; BED regimen: (Bortezomib, Etoposide and Dexamethsone; CR: Complete remission; PR: Partial remission; PD: Disease progression.

Citation: Hu WL, Song JY, Li X, Pei XJ, Zhang JJ, Shen M, Tang R, Pan ZY, Huang ZX. Clinical features and prognosis of multiple myeloma and orbital extramedullary disease: Seven cases report and review of literature. World J Clin Cases 2022; 10(33): 12365-12374
URL: https://www.wjgnet.com/2307-8960/full/v10/i33/12365.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i33.12365